Carphenazine

CHEMBL1201328 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

425.6 g/mol

LogP

3.1

Phase

4

A phenothiazine-class antipsychotic historically used in the treatment of schizophrenia and other psychotic disorders. It shares the dopamine-blocking mechanism of other typical antipsychotics in this class. It is now largely obsolete, having been replaced by newer agents with improved side effect profiles.

分子量

425.6000 g/mol

LogP

3.10

TPSA

72.30 Å²

リピンスキーの五則

適合

作用機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2

InChI

InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3

Molecular Formula

C24H31N3O2S

HBD / HBA

1 / 6

回転可能結合数

8

重原子数

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A phenothiazine-class antipsychotic historically used in the treatment of schizophrenia and other psychotic disorders. It shares the dopamine-blocking mechanism of other typical antipsychotics in this class. It is now largely obsolete, having been replaced by newer agents with improved side effect profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Carphenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201328. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 18104. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Carphenazine PillFYIで

構造

クイックデータ

分子式: C24H31N3O2S

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.